SLC11A2: A Protein with Broad Potential as A Drug Target Or Biomarker

Target Name: SLC11A2

NCBI ID: G4891

SLC11A2

SLC11A2: A Protein with Broad Potential as A Drug Target Or Biomarker

SLC11A2 (Simple Local Connectivity Cluster 11.2) is a protein that is expressed in various tissues throughout the body. It is a member of the SLC family, which is known for its involvement in the transport of various molecules across cell membranes. One of the most interesting aspects of SLC11A2 is its potential as a drug target or biomarker.

SLC11A2 has been shown to play a role in a variety of physiological processes in the body. For example, it has been shown to be involved in the regulation of ion and water transport in the brain, as well as in the development and maintenance of the blood-brain barrier. It is also involved in the regulation of pain perception and neurotransmitter release.

SLC11A2 has also been shown to be involved in the development of certain diseases, such as Alzheimer's disease and Parkinson's disease. These conditions are characterized by the progressive loss of brain cells and the buildup of neurodegeneration, leading to a range of symptoms such as memory loss, stiffness, and difficulty with movement.

The potential drug targets for SLC11A2 are vast, and could include a variety of different therapeutic approaches. For example, one possibility is to target SLC11A2 directly with small molecules, such as drugs that can modulate its activity. Another possibility is to target SLC11A2 with antibodies, such as those that can be used to detect and remove the protein from the brain.

Another approach to targeting SLC11A2 is to use drugs that modulate the activity of other proteins that are involved in the regulation of SLC11A2. For example, one possibility is to use drugs that inhibit the activity of enzymes that regulate SLC11A2, such as the sodium/potassium pump.

In addition to its potential as a drug target, SLC11A2 is also a potential biomarker for a variety of diseases. For example, it has been shown to be involved in the development of Alzheimer's disease, and may be used as a diagnostic marker for this condition. It is also involved in the regulation of pain perception, and may be used as a biomarker for the development of chronic pain.

Overall, SLC11A2 is a protein that has a wide range of potential applications as a drug target or biomarker. Further research is needed to fully understand its role in the regulation of various physiological processes, and to develop effective therapies based on this protein.

Protein Name: Solute Carrier Family 11 Member 2

Functions: Proton-coupled metal ion symporter operating with a proton to metal ion stoichiometry of 1:1 (PubMed:17109629, PubMed:22736759, PubMed:25491917, PubMed:17293870, PubMed:25326704). Selectively transports various divalent metal cations, in decreasing affinity: Cd(2+) > Fe(2+) > Co(2+), Mn(2+) >> Zn(2+), Ni(2+), VO(2+) (PubMed:17109629, PubMed:22736759, PubMed:25491917, PubMed:17293870, PubMed:25326704). Essential for maintenance of iron homeostasis by modulating intestinal absorption of dietary Fe(2+) and TF-associated endosomal Fe(2+) transport in erythroid precursors and other cells (By similarity). Enables Fe(2+) and Mn(2+) ion entry into mitochondria, and is thus expected to promote mitochondrial heme synthesis, iron-sulfur cluster biogenesis and antioxidant defense (PubMed:24448823) (By similarity). Can mediate uncoupled fluxes of either protons or metal ions

The "SLC11A2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC11A2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets